A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.
Also called NCT04516291
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 286 participants
- Sponsor
- Registry
-
NCT04516291 -
2020-002796-35
-
- Other papers using this trial's data
- Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Poland
- Registry status
- Completed
Technical summary
Registry record NCT04516291. Randomized; triple masking; primary purpose treatment. Start 2020-09-28 (actual); primary completion 2021-09-29 (actual). Results posted on 2022-10-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
- Condition
- Dyslipidemias
- Condition
- Hyperlipidemias
- Condition
- Hyperlipoproteinemias
- Intervention (Drug)
- Vupanorsen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct04516291- Content hash
2353ed1fe09ac86993a00c6ad4e691345e045b2222b54376b916b6bebf9edc00